Dr. David Sugarbaker

• Dr. Alexander is an internationally recognized cancer surgeon and surgical oncologist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.  He is also the associate chairman for clinical research in the University of Maryland Department of Surgery. His research interests include perfusion techniques to treat patients with advanced cancers of the limb, liver, and peritoneal cavity.  Dr. Alexander was formally the deputy director of the NCI’s Center for Cancer Research.
  
  University of Maryland Medical Center
  Greenebaum Cancer Center
  22 S. Greene Street
  Baltimore, MD 21201
  Phone: 410.605.7233 (VA Baltimore)
  email: HRAlexander@smail.umaryland.edu
  
  Baltimore VA Medical Center
  10 North Greene Street
  Baltimore, MD 21201
  (410) 605-7000
  800-463-6295
  http://www.umm.edu/news/releases/hr_alexander.html

• Dr. Cameron is a surgical oncologist with expertise in treating mesothelioma patients at the UCLA Medical School. 
• Dr. Robert Cameron is a member of the Scientific Advisory Board for the Pacific Heart, Lung, & Blood Institute (PHLBI, www.phlbi.org).  Dr. Cameron has been at the forefront of developing innovative therapies for extending the lives of mesothelioma patients.  Dr. Cameron’s research plan for PHLBI includes programs involving Immunotherapy and Screening/Early Detection/Prevention.  Dr. Cameron's research plan also includes investigation into much-needed administrative improvements in medical care which will provide patients with additional knowledge, security, and control regarding their treatment.  Click here to see the details of Dr. Cameron's research plan.
• 11818 Wilshire Blvd., Suite 200
  Los Angeles, California 90025
  Phone: 310.794.7333 or 310.231.2130
  email: rcameron@mednet.ucla.edu.
• "Improved Survival with Interferon Alpha Maintenance Therapy Following Pleurectomy/Decortication and Radiation for Malignant Pleural Mesothelioma," as presented by Dr. Robert Cameron to the Society of Thoracic Surgeons, January 30, 2006.
• EPP vs P/D: The Great Debate. Dr. Cameron favors the Pleurectormy/Decortication (10/29/06)
• Anatomy of a Successful P/D (photos).  Dr. Robert Cameron, September 13, 2005
• "Rational Versus Radical Therapy For Mesothelioma: A New Approach,"  Dr. Robert Cameron, UCLA Medical School, presented at MARF Symposium in Las Vegas, October 16, 2004.  Copyright of Dr. Robert Cameron.  Do not copy without permission (11/18/04)
• UCLA Proposes Comprehensive Mesothelioma Translational Research Program (5/10/04)

• Dr. Kaiser is a cardiothoracic surgeon at the University of Pennsylvania Center for Lung Cancer & Related Disorders.
  University of Pennsylvania
  4th Floor, Philadelphia, PA 19104.
  Phone: 215.662.7538;
  email: Kaiser@mail.med.upenn.edu.
  http://www.uphs.upenn.edu/surgery/faculty/lrk.html

• Dr. Loggie is Professor of Surgery and Director for:
  Cancer Center
  Creighton University Medical Center
  601 N. 30th St, Suite 3700
  Omaha, NE 68131
  Phone: 402-280-3273
  email: bwl01656@creighton.edu
• Treatment and Prevention of Malignant Ascites Associated with Disseminated Intraperitoneal Malignancies by Aggressive Combined-Modality Therapy (9/29/04)
• Intraperitoneal Hyperthermic Chemotherapy (IPHC) for Peritoneal Carcinomatosis and Malignant Ascites. Creighton University Medical Center (CUMU) Cancer Center (9/29/04)
• http://www.help4cancer.com
• "Promising" Results from Peritoneal Mesothelioma Studies at NCI and Wake Forest, December 20, 1997

• Dr. Harvey Pass is Professor and Chief of the Division of Thoracic Surgery and Thoracic Oncology at the New York University School of Medicine and Comprehensive Cancer Center.  Dr. Pass has studied pleural mesothelioma since 1988 when he was the Head of Thoracic Oncology and Senior Investigator of the Surgery Branch of the National Cancer Institute in Bethesda. Dr. Pass combines cytoreductive surgery, either EPP or pleurectomy, with innovative or standard adjuvant therapies including novel antiangiogenesis inhibitors postoperatively or chemotherapy combinations. His Thoracic Oncology laboratory is pursuing the study of proteins (proteomics) and gene expression profiles in mesothelioma to develop new early detection strategies, as well as designing alternate innovative treatments which use novel proteins as targets for mesothelioma.  More...
• Curriculum Vitae (resume), Dr. Harvey Pass. March 26, 2003
• Dr. Pass is the Chairman of the Science Advisory Board of the Mesothelioma Applied Research Foundation (MARF).
• Professor and Chief, Division of Thoracic Surgery and Thoracic Oncology
  Department of Cardiothoracic Surgery
  NYU School of Medicine and Comprehensive Cancer Center
  530 1^st Avenue, 9V
  New York, New York 10016
  Phone: 212.263.7417
  email: passh01@med.nyu.edu
• Malignant Pleural Mesothelioma: Surgical Roles and Novel Therapies, preface by RGW (2/7/02)
• Photo Dynamic Therapy, Surgery by Dr. Harvey Pass and Chemotherapy Help 35 Year Old's Battle Against Mesothelioma
• Preoperative Tumor Volume is Associated With Outcome in MM, (2/8/98)
• Update on Dr. Harvey Pass' Research:  (10/6/97)

• Dr. Robinson is a thoracic surgical oncologist with expertise in treating mesothelioma patients.
• Dr. Robinson is on the Science Advisory Board of the Mesothelioma Applied Research Foundation (MARF).
  H. Lee Moffitt Cancer Center & Research Institute
  12902 Magnolia Drive
  Tampa, Florida 33612-9497
  Phone: 813.979.3050
  email: robinson@moffitt.usf.edu.
  http://www.moffitt.usf.edu
• Thoracic Surgeon, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

• Dr. W. Roy Smythe is involved in the surgical diagnosis and treatment of mesothelioma patients. He has designed a pilot protocol at M. D. Anderson for malignant pleural mesothelioma involving aggressive surgical therapy followed by intensity modulated radiation therapy (IMRT). In the laboratory, he was involved in the initial research work evaluating gene therapy for this disease in the mid 1990's at the University of Pennsylvania. He is currently evaluating a number of novel gene therapy and molecular approaches to the treatment of this disease, and hopes to bring one or more of these to the clinic in the next year.
• Curriculum Vitae (resume), Dr. W.Roy Smythe.  October 16, 2001
• Dr. Smythe is on the Science Advisory Board of the Mesothelioma Applied Research Foundation (MARF).
• Preclinical Data of Introgen's INGN 241 Demonstrate Broad Anti-Cancer Activity In Multiple Tumor Types as Monotherapy and in Combination; Update on Gene Therapy Research at MDA under Dr. Roy Smythe  (6/14/01)
• Dr. W. Roy Smythe
  Professor & Chairman
  Texas A&M University Health Sciences Center
  Scott & White Hospital and Clinic
  Department of Surgery
  2401 South 31st Street
  Temple, TX 76501
  Phone:  254.724.2595
  Fax: 254.724.2786
  email:  rsmythe@swmail.sw.org

• Dr. Sugarbaker is a surgical oncologist with expertise in treating mesothelioma patients. Dr. Sugarbaker has pioneered the "tri-modal" therapy approach.
  Brigham & Womens Hospital
  75 Francis Street, Boston
  Massachusetts 02115
  Phone: 617.732.6824
  email: djsugarbak@bic.bwh.havard.edu.
• Summary of Dr. Sugarbaker's Results Using Tri-Modal Therapy on 183 Patients from 1980 to 1997.
• Multimodality Management of MM:  Dr. David Sugarbaker, January 1999
• Current Therapy for Mesothelioma, Sugarbaker et al, 1997
  The Division of Thoracic Surgery at the Brigham and Women's Hospital in Boston Massachusetts provides diagnostic and treatment services to patients with benign and malignant neoplasms and other disorders of the lung, esophagus, mediastinum and chest wall. Their website provides complete review of services available, how to set up an appointment, whom to call, and how to prepare for surgery and rehabilitate afterwards. Check it out. http://www.chestsurg.org

• Dr. Taub is a medical oncologist who directs the Connective Tissue Oncology Program at the Herbert Irving Comprehensive Cancer Center, where there are a number of ongoing multimodality studies of patients with pleural and peritoneal mesothelioma.
• Dr. Taub is on the Science Advisory Board of the Mesothelioma Applied Research Foundation (MARF).
  Columbia University College of Physicians and Surgeons
  161 Fort Washington Avenue
  New York, New York 10032
  Phone: 212.305.4076
  email: rnt1@columbia.edu
• Phase II Trial of Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for Treatment of Peritoneal Mesothelioma  (11/14/01)
• New Trial Using Tri-Modal Therapy for Peritoneal Mesothelioma in New York with Dr. Robert N. Taub.

• Dr. Vallières is a surgical oncologist who since 1997 has been the principal investigator of a Phase II multi-modal trial for mesothelioma patients at the University of Washington Medical Center.  He now practices at the Swedish Cancer Institute.
• Dr. Vallières is on the Science Advisory Board of the Mesothelioma Applied Research Foundation (MARF).
  
  University of Washington School of Medicine
  Eric Vallières MD FRCSC
  Thoracic Oncology
  Swedish Cancer Institute
  1221 Madison Street suite 400
  Seattle, WA 98104
  Phone: 206.-215.6800
  Fax: 206.215.6801
  email: eric.vallieres@swedish.org
   
• Dr. Eric Vallières: Engaged on all Fronts. Seattle, Washington